Dashboard
Manage Tickers

LEGNLegend Biotech Corp

Nasdaq legendbiotech.com


$ 45.73 $ 1.38 (3.11 %)    

Wednesday, 15-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 45.76
$ 44.99
$ 0.00 x 0
$ 0.00 x 0
$ 44.67 - $ 45.91
$ 42.08 - $ 77.32
1,049,142
na
16.65B
$ 0.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-maintains-outperform-on-legend-biotech-raises-price-target-to-86
RBC Capital Maintains Outperform on Legend...
05/14/2024 15:31:54

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target fro...

legend-biotech-stock-a-deep-dive-into-analyst-perspectives-14-ratings
Legend Biotech Stock: A Deep Dive Into Ana...
05/14/2024 12:00:19

hc-wainwright--co-maintains-buy-on-legend-biotech-lowers-price-target-to-86
HC Wainwright & Co. Maintains Buy on Legen...
05/14/2024 10:56:55

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price targe...

legend-biotech-expects-cash-and-equivalents-of-13b-as-of-march-end-to-provide-financial-runway-into-2026-when-it-anticipates-achieving-an-operating-profit
Legend Biotech Expects Cash And Equivalent...
05/13/2024 11:04:50

legend-biotech-q1-2024-gaap-eps-016-beats-034-estimate-sales-93991m-miss-152631m-estimate
Legend Biotech Q1 2024 GAAP EPS $(0.16) Be...
05/13/2024 11:02:15

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34...

hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target
HC Wainwright & Co. Reiterates Buy on Lege...
05/09/2024 18:56:45

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target
HC Wainwright & Co. Reiterates Buy on Lege...
04/23/2024 10:19:23

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

legend-biotech-announces-carvykti-approved-by-the-european-commission-for-second-line-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma
Legend Biotech Announces Carvykti Approved...
04/22/2024 17:09:33

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Bi...

fda-mandates-boxed-warning-for-bristol-myers-johnson--johnson-car-t-based-blood-cancer-therapies
FDA Mandates "Boxed Warning" For Bristol M...
04/19/2024 13:28:52

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...

analyst-ratings-for-legend-biotech
Analyst Ratings For Legend Biotech
04/17/2024 14:01:36

scotiabank-upgrades-legend-biotech-to-sector-outperform-maintains-price-target-to-65
Scotiabank Upgrades Legend Biotech to Sect...
04/17/2024 12:20:16

Scotiabank analyst George Farmer upgrades Legend Biotech (NASDAQ:LEGN) from Sector Perform to Sector Outperform and maintain...

hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target
HC Wainwright & Co. Reiterates Buy on Lege...
04/16/2024 17:10:10

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

legend-biotech-earlier-announced-carvykti-generated-approximately-157m-in-net-trade-sales-during-the-quarter-ended-mar-31
Legend Biotech Earlier Announced CARVYKTI ...
04/16/2024 15:42:49

johnson--johnsons-carvykti-stands-ahead-of-bristol-myers-rival-blood-cancer-therapy-with-fda-approval-for-wider-population
Johnson & Johnson's Carvykti Stands Ahead ...
04/08/2024 18:19:35

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients...

on-friday-april-5-2024-legend-biotech-reported-carvykti-becomes-the-first-and-only-bcma-targeted-car-t-cell-therapy-approved-by-the-fda-for-second-line-treatment-of-multiple-myeloma
On Friday April 5, 2024, Legend Biotech Re...
04/08/2024 07:42:07

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Bi...

cantor-fitzgerald-initiates-coverage-on-legend-biotech-with-overweight-rating-announces-price-target-of-82
Cantor Fitzgerald Initiates Coverage On Le...
04/03/2024 11:47:47

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and an...

unveiling-9-analyst-insights-on-legend-biotech
Unveiling 9 Analyst Insights On Legend Bio...
04/01/2024 12:01:27

hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target
HC Wainwright & Co. Reiterates Buy on Lege...
04/01/2024 10:12:24

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

genscript-losses-shrink-on-strong-growth-for-cancer-cell-therapy
GenScript Losses Shrink On Strong Growth F...
03/20/2024 15:30:12

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Bio...

legend-biotech-filed-for-mixed-shelf-offering-size-not-disclosed-
Legend Biotech Filed For Mixed Shelf Offer...
03/19/2024 12:00:19

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION